


# Definitions of Suboptimal Response to DMT and Criteria for Switching Therapy

## Modified Rio scoring system<sup>1,2</sup>

Defined after first year of therapy

Criteria (predictive of disability progression)	Points
1 relapse	1
≥2 relapses	2
>5 new T2 lesions on MRI	1

## Scoring (total of points from relapse and MRI criteria)



## No evidence of disease activity (NEDA)<sup>3,4</sup>

Definitions vary



## AAN Practice Guideline<sup>5</sup>

Suboptimal response; consider switch




AAN, American Academy of Neurology.

1. Sormani MP et al. *Mult Scler.* 2013;19:605-612; 2. Sormani MP, De Stefano N. *Nat Rev Neurol.* 2013;9:504-512; 3. Giovannoni G et al. *Mult Scler.* 2017;23:1179-1187;

4. Kappos L et al. *Mult Scler.* 2016;22:1297-1305. 5. Rae-Grant A et al. *Neurology.* 2018;90:777-788.

# Individualized Treatment Decisions: Therapy-Related Considerations



1. Soelberg Sorensen P. *Acta Neurol Scand.* 2017;136:168-186; 2. Ontaneda D et al. *Lancet Neurol.* 2019;18:973-980; 3. Freedman MS et al. *Can J Neurol Sci.* 2020;47:437-455.

# Individualized Treatment Decisions: Patient-Related Considerations



## Disease characteristics and risk for future disability

- Age at disease onset
- Relapse frequency and severity
- Degree of recovery from relapse

## Comorbidities and risk factors for adverse events

## Adherence to medication and safety monitoring requirements

## Preferences and risk tolerance



## Access to medication